StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)

StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report issued on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, Maxim Group raised shares of Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a report on Thursday, July 11th.

Brainstorm Cell Therapeutics Price Performance

Shares of Brainstorm Cell Therapeutics stock opened at $0.32 on Wednesday. Brainstorm Cell Therapeutics has a fifty-two week low of $0.13 and a fifty-two week high of $1.81. The firm has a fifty day moving average price of $0.37 and a two-hundred day moving average price of $0.43. The company has a market cap of $22.36 million, a PE ratio of -1.00 and a beta of 0.37.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. Analysts expect that Brainstorm Cell Therapeutics will post -0.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC acquired a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned 0.12% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities and Exchange Commission. 14.33% of the stock is currently owned by institutional investors and hedge funds.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.